General Information of Drug (ID: DMEY1F3)

Drug Name
Zabofloxacin Drug Info
Synonyms DW-224a; DW-224aa; PB-101; Zabofloxacin (oral), IASO Pharma/DHP
Indication
Disease Entry ICD 11 Status REF
Pneumonia CA40 Phase 3 [1]
Cross-matching ID
PubChem CID
10388396
TTD Drug ID
DMEY1F3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [3]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [4]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [4]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [4]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [4]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [4]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [4]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [6]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [4]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [4]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [4]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [4]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [4]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [6]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [7]
Delafloxacin Meglumine DMVTU5Q Acute bacterial skin infection 1C41 Approved [8]
Moxifloxacin DMU8V4S Bacterial infection 1A00-1C4Z Approved [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [2]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [2]

References

1 ClinicalTrials.gov (NCT01658020) A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg. U.S. National Institutes of Health.
2 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
3 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.